226 related articles for article (PubMed ID: 27846237)
1. Integrated Genomics Identifies miR-32/MCL-1 Pathway as a Critical Driver of Melanomagenesis: Implications for miR-Replacement and Combination Therapy.
Mishra PJ; Mishra PJ; Merlino G
PLoS One; 2016; 11(11):e0165102. PubMed ID: 27846237
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK
Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853
[TBL] [Abstract][Full Text] [Related]
3. Joint action of miR-126 and MAPK/PI3K inhibitors against metastatic melanoma.
Pedini F; De Luca G; Felicetti F; Puglisi R; Boe A; Arasi MB; Fratini F; Mattia G; Spada M; Caporali S; Biffoni M; Giuliani A; Carè A; Felli N
Mol Oncol; 2019 Sep; 13(9):1836-1854. PubMed ID: 31115969
[TBL] [Abstract][Full Text] [Related]
4. Conjunctival malignant melanoma in Denmark: epidemiology, treatment and prognosis with special emphasis on tumorigenesis and genetic profile.
Larsen AC
Acta Ophthalmol; 2016 May; 94 Thesis 1():1-27. PubMed ID: 27192168
[TBL] [Abstract][Full Text] [Related]
5. Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b.
Vergani E; Di Guardo L; Dugo M; Rigoletto S; Tragni G; Ruggeri R; Perrone F; Tamborini E; Gloghini A; Arienti F; Vergani B; Deho P; De Cecco L; Vallacchi V; Frati P; Shahaj E; Villa A; Santinami M; De Braud F; Rivoltini L; Rodolfo M
Oncotarget; 2016 Jan; 7(4):4428-41. PubMed ID: 26684239
[TBL] [Abstract][Full Text] [Related]
6. Integrated Genomics Identifies miR-181/TFAM Pathway as a Critical Driver of Drug Resistance in Melanoma.
Barbato A; Iuliano A; Volpe M; D'Alterio R; Brillante S; Massa F; De Cegli R; Carrella S; Salati M; Russo A; Russo G; Riccardo S; Cacchiarelli D; Capone M; Madonna G; Ascierto PA; Franco B; Indrieri A; Carotenuto P
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670365
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic BRAF signalling increases Mcl-1 expression in cutaneous metastatic melanoma.
McKee CS; Hill DS; Redfern CP; Armstrong JL; Lovat PE
Exp Dermatol; 2013 Nov; 22(11):767-9. PubMed ID: 24118207
[TBL] [Abstract][Full Text] [Related]
8. miR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma.
Stark MS; Bonazzi VF; Boyle GM; Palmer JM; Symmons J; Lanagan CM; Schmidt CW; Herington AC; Ballotti R; Pollock PM; Hayward NK
Oncotarget; 2015 Jul; 6(19):17753-63. PubMed ID: 25980496
[TBL] [Abstract][Full Text] [Related]
9. Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells.
Vitiello M; Tuccoli A; D'Aurizio R; Sarti S; Giannecchini L; Lubrano S; Marranci A; Evangelista M; Peppicelli S; Ippolito C; Barravecchia I; Guzzolino E; Montagnani V; Gowen M; Mercoledi E; Mercatanti A; Comelli L; Gurrieri S; Wu LW; Ope O; Flaherty K; Boland GM; Hammond MR; Kwong L; Chiariello M; Stecca B; Zhang G; Salvetti A; Angeloni D; Pitto L; Calorini L; Chiorino G; Pellegrini M; Herlyn M; Osman I; Poliseno L
Oncotarget; 2017 Apr; 8(15):25395-25417. PubMed ID: 28445987
[TBL] [Abstract][Full Text] [Related]
10. In Vitro Biophysical and Biological Characterization of Lipid Nanoparticles Co-Encapsulating Oncosuppressors miR-199b-5p and miR-204-5p as Potentiators of Target Therapy in Metastatic Melanoma.
Fattore L; Campani V; Ruggiero CF; Salvati V; Liguoro D; Scotti L; Botti G; Ascierto PA; Mancini R; De Rosa G; Ciliberto G
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32178301
[TBL] [Abstract][Full Text] [Related]
11. miR-137 and miR-197 Induce Apoptosis and Suppress Tumorigenicity by Targeting MCL-1 in Multiple Myeloma.
Yang Y; Li F; Saha MN; Abdi J; Qiu L; Chang H
Clin Cancer Res; 2015 May; 21(10):2399-411. PubMed ID: 25724519
[TBL] [Abstract][Full Text] [Related]
12. miR-200c/Bmi1 axis and epithelial-mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment.
Liu S; Tetzlaff MT; Wang T; Yang R; Xie L; Zhang G; Krepler C; Xiao M; Beqiri M; Xu W; Karakousis G; Schuchter L; Amaravadi RK; Xu W; Wei Z; Herlyn M; Yao Y; Zhang L; Wang Y; Zhang L; Xu X
Pigment Cell Melanoma Res; 2015 Jul; 28(4):431-41. PubMed ID: 25903073
[TBL] [Abstract][Full Text] [Related]
13. The tumour suppressor, miR-137, inhibits malignant melanoma migration by targetting the TBX3 transcription factor.
Peres J; Kwesi-Maliepaard EM; Rambow F; Larue L; Prince S
Cancer Lett; 2017 Oct; 405():111-119. PubMed ID: 28757416
[TBL] [Abstract][Full Text] [Related]
14. Exosome-mediated transfer of miR-222 is sufficient to increase tumor malignancy in melanoma.
Felicetti F; De Feo A; Coscia C; Puglisi R; Pedini F; Pasquini L; Bellenghi M; Errico MC; Pagani E; Carè A
J Transl Med; 2016 Feb; 14():56. PubMed ID: 26912358
[TBL] [Abstract][Full Text] [Related]
15. miR-200c inhibits melanoma progression and drug resistance through down-regulation of BMI-1.
Liu S; Tetzlaff MT; Cui R; Xu X
Am J Pathol; 2012 Nov; 181(5):1823-35. PubMed ID: 22982443
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma.
Jin L; Hu WL; Jiang CC; Wang JX; Han CC; Chu P; Zhang LJ; Thorne RF; Wilmott J; Scolyer RA; Hersey P; Zhang XD; Wu M
Proc Natl Acad Sci U S A; 2011 Sep; 108(38):15840-5. PubMed ID: 21896753
[TBL] [Abstract][Full Text] [Related]
17. Lin28B promotes melanoma growth by mediating a microRNA regulatory circuit.
Zhang Z; Zhang S; Ma P; Jing Y; Peng H; Gao WQ; Zhuang G
Carcinogenesis; 2015 Sep; 36(9):937-45. PubMed ID: 26071398
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-15b represents an independent prognostic parameter and is correlated with tumor cell proliferation and apoptosis in malignant melanoma.
Satzger I; Mattern A; Kuettler U; Weinspach D; Voelker B; Kapp A; Gutzmer R
Int J Cancer; 2010 Jun; 126(11):2553-62. PubMed ID: 19830692
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of mcl-1 by small interfering RNA sensitizes resistant melanoma cells to fas-mediated apoptosis.
Chetoui N; Sylla K; Gagnon-Houde JV; Alcaide-Loridan C; Charron D; Al-Daccak R; Aoudjit F
Mol Cancer Res; 2008 Jan; 6(1):42-52. PubMed ID: 18234961
[TBL] [Abstract][Full Text] [Related]
20. [Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge].
Capovilla M
Ann Pathol; 2013 Dec; 33(6):375-85. PubMed ID: 24331719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
